Extending in vivo half-life of therapeutic proteins (L-11944) . : NR16-182/2017E-PDF
“Post-translational modifications of therapeutic proteins are commonly made to improve their circulating half-life, thereby enhancing their efficiency. Numerous strategies have been employed towards this end, including covalent modification, such as through PEGylation, the chemical addition of chains of polyethylene glycol (PEG) to therapeutic proteins. However, PEGylation relies on chemical conjugation of PEG chains to free amino groups or engineered cysteine residues on the protein, which can lead to heterogeneously-modified proteins whose activity can be adversely affected. To address this, the NRC has developed a site-specific, two-step in vitro modification process whereby polysialic acid (PSA) is enzymatically added to existing glycans, resulting in proteins with greater stability, solubility and circulating half-life”--Highlights.
Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.847765&sl=1
| Ministère/Organisme | National Research Council Canada. |
|---|---|
| Titre | Extending in vivo half-life of therapeutic proteins (L-11944) . |
| Type de publication | Monographie |
| Langue | [Anglais] |
| Autres langues publiées | [Français] |
| Format | Électronique |
| Document électronique | |
| Note(s) | Issued also in French under title: Accroître la demi-vie in vivo des protéines thérapeutiques (L-11944). Caption title. "December 2017." Issued also in print format. |
| Information sur la publication | [Ottawa] : National Research Council Canada, [2018] |
| Description | [1] p. |
| ISBN | 9780660240114 |
| Numéro de catalogue |
|
| Descripteurs | Recombinant proteins Protein engineering |
Demander des formats alternatifs
Pour demander une publication dans un format alternatif, remplissez le formulaire électronique des publications du gouvernement du Canada. Utilisez le champ du formulaire «question ou commentaire» pour spécifier la publication demandée.- Date de modification :